Mutants of interleukin-1 receptor antagonist

US8303945B2 · kind B2 · utility

Assignee

• ALLIGATOR BIOSCIENCE AB · SE

Inventors

• Eva Dahlen · Lund, SE
• Karin Elisabeth Barchan · Vellinge, SE
• Patrick Thomas Höjman · Eidsvold, AU
• Cecilia Ann-Christin Malmborg Hager · Helsingborg, SE
• Marie Asa Ingegerd Karlsson · Lund, SE
• Mats Peter Anderson · Vaxholm, SE
• Björn Walse · Lund, SE

Key dates

• Filing date: May 1, 2008
• Grant date: Nov 6, 2012
• Expiry date: May 1, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/545
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide, fusion or derivative is or comprises a polypeptide variant of amino acid sequence SEQ ID NO: 1 comprising or consisting of substitutions at one or more of the following amino acid mutations of SEQ ID NO: 1: Q29K, P38Y, P38R, L42W, D47N, E52R, H54R, E90Y, Q129L, Q129N, M136N, M136D and Q149K. Also provided are pharmaceutical compositions of the above polypeptide, fusion or derivative, as well as uses of the same for treating a disease or condition capable of being treated by an agent which inhibits the function of IL-1 receptors.